Eli Lilly and Company · 7 hours ago
Director, Immunoassay-based Biomarker Discovery and Analysis - Neuroscience
Boston, MA
Full-time
Onsite
Lead/Staff, Director/Executive
$164K/yr - $282K/yr
5+ years expEli Lilly and Company is a global healthcare leader headquartered in Indianapolis, Indiana. They are seeking a Director for Immunoassay-based Biomarker Discovery and Analysis in Neuroscience, responsible for designing and validating biomarker methods for clinical trials in neurodegenerative diseases, and collaborating with various stakeholders to ensure successful integration into clinical programs.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Design, development and validation of novel immunoassay-based biomarker methods, as well as applications of these methods for early- and late-phase clinical trials in neurodegenerative diseases, including Alzheimer’s, Parkinson’s, ALS, and rare brain disorders
Work with project team leads, including Dr. Kaj Blennow (Vice President of Neuroscience Biomarker Development), and other associates to perform experiments to support both the preclinical and clinical characterization and evaluation of therapeutic molecules through biomarker assay development
Assist with the planning and execution of immunoassay method developments, method optimization and validation, as well as sample analyses from cohorts, working with both internal and external partners in complex studies
Work directly on-site with methods in the laboratory, and with summarizing and reporting method status of results for internal partners
Implement assay validation procedures to deliver high performance biomarker assays for preclinical and clinical sample analyses
Collaborate cross-functionally with internal stakeholders (medical, operations, statistics, regulatory) and external partners (CROs, academic institutions) to ensure biomarker validation and successful integration into clinical programs
Qualification
Required
Master's and/or PhD in Neuroscience, Biochemistry or a related scientific field, with 5+ years of industry, academic, or postdoctoral experience in biomarker development, with recognized expertise in mass spectrometry-based assays for brain diseases
Preferred
Must have an understanding of the principles for antibodies and other affinity-based molecules, for immunoassay design and protein biomarker quantification as well as documented hands-on experience in immunoassay development and validation for biomarker applications in clinical diagnostics, clinical trials, or preclinical sample analysis
Must be technically skilled to in the field of qualitative (e.g. electrophoresis techniques, Westen blot) and quantitative (e.g. ELISA, MSD, Ella, Simoa) immunoassay-based analyses
Proven leadership in managing and mentoring biomarker research teams in academic or industry settings
Experience in ultrasensitive technologies (e.g. NuLISA) and protein separation and purification techniques (e.g. HPLC, immunoprecipitation) is a merit
Excellent communication and collaboration skills, with the ability to present to influence both internal and external stakeholders
Benefits
Company bonus
Eligibility to participate in a company-sponsored 401(k)
Pension
Vacation benefits
Eligibility for medical, dental, vision and prescription drug benefits
Flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts)
Life insurance and death benefits
Certain time off and leave of absence benefits
Well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities)
Company
Eli Lilly and Company
We're a medicine company turning science into healing to make life better for people around the world.
10001+ employees
H1B Sponsorship
Eli Lilly and Company has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (404)
2024 (236)
2023 (167)
2022 (133)
2021 (57)
2020 (52)
Funding
Current Stage
Public CompanyTotal Funding
$6.5M2024-02-12Post Ipo Debt· $6.5M
1978-01-13IPO
Leadership Team
David Ricks
Chair, CEO
Lucas Montarce
Executive Vice President and Chief Financial Officer
Recent News
2025-12-30
2025-12-30
Company data provided by crunchbase